A study of RA treatment by targeting FLAs with BMSC-EVs containing miR-34a reported notable efficacy via the cyclin I/ataxia-telangiectasia mutated symbol/ataxia-telangiectasia and Rad3-related protein/p53 signaling pathways [99]. The gene discussed is TP53; the disease is rheumatoid arthritis.